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A B S T R A C T
Objectives: This study was designed to examine the change in mean platelet volume (MPV) over the
course of infective endocarditis (IE) and also the association between MPV and complications including
embolic events in IE.
Methods: Forty patients (26 male, mean age 46  15 years) who were hospitalized with a diagnosis of IE at
the Department of Cardiology, Erciyes University, from March 2005 to August 2008, were retrospectively
evaluated. The diagnosis of IE was made clinically and was conﬁrmed with Duke’s criteria. The erythrocyte
sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), and MPV were measured before
treatment and periodically during the follow-up period, until discharge.
Results: There were 27 cases of native valve endocarditis and 13 of prosthetic valve endocarditis. While
31 patients were treatedmedically, an operation was performed in nine patients because of unsuccessful
medical therapy. On admission, mean MPV was 10.8  1.1 ﬂ, ESR was 82  26 mm/h, and hs-CRP was
110  72 mg/l. Seven patients died: one intraoperatively, three patients postoperatively, and three patients
during medical treatment. With the exception of these seven patients, ESR and hs-CRP were signiﬁcantly
reduced in all patients at discharge compared to levels at hospitalization (ESR 82  26 to 32  22, p = 0.001
and hs-CRP 110  72 to 25  15, p = 0.001). Similarly, we detected a signiﬁcant decrease in MPV from
hospitalization to discharge, i.e., from the active period of the disease to recovery (10.8  1.1 to 9.7  0.8 ﬂ,
p = 0.002). In addition, MPV was found to be signiﬁcantly higher in patients with observed embolic
complications (11.5 vs. 10.3 ﬂ, p = 0.001), other complications (11.0 vs. 10.2 ﬂ, p = 0.001), and death (11.1 vs.
10.4 ﬂ, p = 0.005).
Conclusion: MPV can be used as an activity criterion in IE, like ESR and hs-CRP. Also, high MPV is
associated with a poor prognosis and adverse outcomes, and predicts complications including embolic
events.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infective endocarditis (IE) remains a very serious health
problem, afﬂicting 2–7 cases/100 000 person-years, with a high
mortality rate despite all the improvements in diagnosis,
treatment, and management.1–3 Over the last few decades the
incidence of complications has not changed much. Among these
complications, embolic events occur in 20% to 43% of patients and
are associated with a higher mortality.4–6
It is known that procoagulant changes in platelet activity may
be established in patients with IE, especially in those with§ Presented at the 24th National Congress of Cardiology; Istanbul, Turkey, October
24–27, 2008.
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hypercoagulable state can facilitate embolization, one of the
major causes of death. Although clinical studies using aspirin
therapy in order to prevent embolic complications have had
controversial outcomes, many laboratory ﬁndings of this hyper-
coagulable state, such as increased platelet factor 4, increased
thrombin–antithrombin complex, increased plasminogen activa-
tor inhibitor-1 levels, and elevated levels of antiphospholipid
antibodies, have been conﬁrmed.7,8
To date, the only approach to the prevention of embolic
complications is effective antibiotic therapy. Mean platelet volume
(MPV), which is generally overlooked by clinicians and is a
parameter routinely provided by a full blood count analyzer, not
requiring any complex or expensive technologies, correlates with
platelet function and activation.9–11 To our knowledge, no study
has yet focused on MPV in patients with IE. Therefore our aim was
to investigate whether or not MPV changes during effectiveses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline characteristics of the patients
Characteristic N=40
Age (years) 4615
Gender (F/M) 14/26
Follow-up period (days) 246
Cardiac risk factors
Previous endocarditis 2 (5%)
Pre-existing native valve disease 13 (33%)
Prosthetic valve 13 (33%)
Non-cardiac risk factors
Diabetes mellitus 8 (20%)
Chronic renal failure 6 (15%)
Therapy
Surgical therapy 9 (23%)
Medical therapy 31 (78%)
Complications
Congestive heart failure 10 (25%)
Renal failure 2 (5%)
Embolism 7 (18%)
Paravalvular abscess 2 (5%)
In-hospital death (%) 7 (18%)
Table 2
Laboratory and echocardiographic ﬁndings in patients with infective endocarditis
N=40
Laboratory ﬁndings
Hemoglobin (g/dl) 11.22.6
Leukocytes (109/l) 9.84.7
hs-CRP (mg/l) 11072
ESR (mm/h) 8226
Mean platelet volume (ﬂ) 10.81.1
Echocardiographic ﬁndings
Vegetation 29 (73%)
Abscess 2 (5%)
New dehiscence or new valvular regurgitation 7 (18%)
Left ventricular ejection fraction (%) 5515
hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate.
Figure 1. Mean platelet volume during the course of infective endocarditis.
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relationship between MPV and complications and disease activity
in IE.
2. Methods
We retrospectively studied 40 consecutive deﬁnite IE patients
hospitalized at the Department of Cardiology of our university
from March 2005 to August 2008. The diagnosis of deﬁnite IE was
conﬁrmed using the modiﬁed Duke’s criteria.12
Erythrocyte sedimentation rate (ESR), high-sensitivity C-reac-
tive protein (hs-CRP), and MPV were measured on admission and
periodically during the follow-up period, until discharge or death.
Discharge from the hospital and all-cause in-hospital mortality
were end-points of the study.
Patient clinical characteristics, associated diseases predisposing
to IE, culture results, echocardiographic ﬁndings, laboratory
results, complications appearing during the in-hospital period,
and conditions associated with mortality were obtained from the
hospital registries.
In all patients hospitalized with a preliminary diagnosis of IE,
blood cultures were obtained from three to four separate veins
during the ﬁrst hour, and transthoracic echocardiographic
examinations were undertaken for both diagnosis and to establish
the presence of complications. In cases of poor image quality in
patientswith prosthetic valves, transesophageal echocardiography
was used. A Vingmed system V (Vingmed GE System 5, Horten,
Norway) echocardiography device with a 2.5 MHz transducer was
used for echocardiographic examinations.
MPV was measured in blood samples collected in EDTA tubes,
which were analyzed by ﬂow cytometry in an automated
hematology analysis system (Sysmex, XT-2000i). hs-CRP was
measured using a BN2 model nephelometer (Dade-Behring). The
normal value range for hs-CRP in our laboratory was 0–6 mg/l and
for MPV was 7.4–10.4 ﬂ.
3. Statistical analysis
SPSS statistical software (SPSS for windows 13.0; SPSS Inc.,
Chicago, IL, USA) was used for all statistical calculations.
Continuous variables are given as mean  standard deviation
(SD) and categorical variables as percentages. Differences between
groups were tested using the Student’s t-test for unpaired data,
analysis of variance, and the Chi-square test when appropriate. A
paired Student’s t-test was used for comparison of the MPV, ESR, and
hs-CRP values before and after treatment in patients with IE.
Statistical signiﬁcance was deﬁned as a p-value of < 0.05.
4. Results
BetweenMarch 2005 and August 2008, 40 patients (26male, 14
female) with a deﬁnite IE diagnosis were managed at the
Department of Cardiology of our university and were included
in the study. Mean patient age was 46  15 years and the mean
follow-up period was 24  6 days. Table 1 shows the demographic
and clinical characteristics of the study patients. There were 27 (67%)
patients with native valve endocarditis and 13 (33%) with prosthetic
valve endocarditis. The most common risk factors predisposing to IE
were the presence of a prosthetic valve, rheumatic valvular disease,
diabetes mellitus, and chronic renal failure.
The microorganism responsible for IE was detected in 56% of
native valve endocarditis cases and 68% of prosthetic valve
endocarditis cases. Coagulase-negative Staphylococcus was found
to be the most common etiologic pathogen in both groups.
On echocardiographic examination, we detected a vegetation in
29 patients (73%), abscess in two patients (5%), and newdehiscence or new valvular regurgitation in seven patients
(18%). The left ventricular ejection fraction was found to be
55  15% (Table 2).
At the time of hospitalization, mean ESR was 82  26 mm/h, hs-
CRPwas 110  72 mg/l, andMPVwas 10.8  1.1 ﬂ (Table 2). Except in
seven of the patients who died, ESR and hs-CRP levels decreased
signiﬁcantly with clinical resolution (ESR 82  26 mm/h to
32  22 mm/h, p = 0.001 and hs-CRP 110  72 mg/l to 25  15 mg/
l, p = 0.001). Similarly, MPVwasmarkedly reduced during the healing
phase of IE (10.8  1.1 to 9.7  0.8 ﬂ, p = 0.002) (Figure 1). The[(Figure_1)TD$FIG]
[(Figure_2)TD$FIG]
Figure 2. Association between mean platelet volume and total complications,
embolic complications, and death.
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differences between the values at the time of hospitalization and
at the time of discharge.
A prosthetic valve replacement was carried out in nine patients,
and of these, four patients died (one intraoperatively and three
postoperatively). Three patients in the group treated medically
also died. Initial MPVs were higher in fatal cases than in those who
survived (11.1 vs. 10.4 ﬂ; p = 0.005). Embolic complications
occurred in seven patients throughout the follow-up period. We
detected higher MPVs in the patients with this catastrophic
complication than in those without (11.5 vs. 10.3 ﬂ; p = 0.001)
(Figure 2).
A total of 21 complications, consisting of congestive heart
failure, renal failure, embolism, and paravalvular abscess, were
seen. These complications were associated with a high MPV (MPV
in complicated patients was 11.0 ﬂ and in uncomplicated patients
was 10.2 ﬂ, p = 0.001) (Figure 2).
The associations of MPV with complications, embolic events,
and death were determined frommeasurements taken at the time
of hospitalization .
Language has been changed throughout; however the following
sentences have undergone more major changes. Please conﬁrm
that these are correct/advise of any changes required.
5. Discussion
IE is an uncommon but severe disease with approximately 20%
in-hospital mortality.13 In brief, its pathogenesis consists of
endothelial injury and erosion caused by hemodynamic and
mechanical stress, which lead to platelet deposition and the
appearance of sterile thrombotic vegetations; these serve as an
environment for bacterial adherence.14 Rheumatic heart disease,
congenital heart disease, degenerative heart disease, parenteral
drug abuse, and prosthetic valves are major predisposing
conditions. Streptococci, enterococci, Staphylococcus aureus, coag-
ulase-negative staphylococci, Gram-negative bacilli, and fungi are
the most common etiologic organisms.15
Although the incidence of acute rheumatic fever and rheumatic
heart disease decrease by the day in developed countries, they
remain important problems in undeveloped and developing
countries.16–18 While the incidence has declined to 20–30% in
North America and Europe since the 1980s, rheumatic valvular
disease is still responsible for more than 50% of IE cases in
Turkey.19–21 However, in our study, a prosthetic valvewas found to
be the major predisposing condition for IE.
Embolic events occur in 20% to 43% of IE cases and are one of the
main causes of death.4–6,22,23 The only establishedmedical therapy
known to reduce the risk of embolism is antimicrobial therapy.24
To date, the use of antiplatelet agents to prevent systemic
embolism has led to controversial outcomes. Chan et al.25demonstrated that the addition of aspirin to antibiotic treatment
did not decrease the risk of embolic events in endocarditis
patients; conversely, Anavekar et al.24 showed a decrease in
embolic events with antiplatelet therapy.
In some investigations, even in the absence of cardiac
involvement, systemic bacterial infections have been demonstrat-
ed as an independent risk factor for an embolic event.26–28
Inﬂammation-induced procoagulant changes may be responsible
for this scenario. Kupferwasser et al. showed that infection-
associated elevated antiphosphoplipid antibodies are associated
with thrombin generation, endothelial cell activation, and major
embolic events in IE.8 Ileri at al. conﬁrmed an inﬂammation-
induced hypercoagulable state in IE patients with embolic
complications, showing increased platelet factor 4, increased
thrombin–antithrombin complex, and increased plasminogen
activator inhibitor-1 levels.7
MPV is a marker of platelet activation, i.e., a larger platelet
volume means both an enzymatically and metabolically more
active platelet than a smaller one. Because these larger platelets
have higher intracellular thromboxane A2 levels and increased
levels of procoagulant surface proteins such as P selectin and
GpIIb/IIIa, they have a greater prothrombotic potential.29 Since the
risk of embolism in IE decreases with antimicrobial therapy, we
hypothesized that MPV would reduce gradually with effective
therapy. Data regarding the association betweenMPV and embolic
complications in IE do not exist in the literature. If such an
association is discovered, MPV might be helpful in recognizing
patients at increased risk of embolic complications. In this report, a
signiﬁcant decrease in MPV with clinical resolution and improve-
ments in known laboratory markers associated with disease
activity, such as ESR and hs-CRP, was detected. In addition, MPV in
the IE patients with embolic complications was higher than in
those patients without these complications. This slight but
signiﬁcant positive association between MPV level and embolic
complications supports our hypothesis.
On the other hand, inﬂammation, a well-known stimulant of
platelets, plays a critical role in the pathogenesis of many diseases
such as ankylosing spondylitis, psoriasis, and rheumatoid arthri-
tis.30–32 To date, only few data are available on MPV and the
interaction between MPV and inﬂammatory markers and disease
activity in inﬂammatory and infectious diseases. Yazici et al.30
demonstrated that patients with ankylosing spondylitis have
signiﬁcantly higher baselineMPV than healthy controls. Theywere
also the ﬁrst to report that MPV is closely correlated with clinical
disease activity in ankylosing spondylitis. After 6 months of
therapy, they found that MPV was markedly decreased, as well as
white blood cell count, ESR, and CRP levels. Consequently, although
they considered that further studies were required, they antici-
pated that MPV could be used as a follow-up marker during the
management of ankylosing spondylitis in the future. Similar
results were observed in another clinical trial investigating MPV in
rheumatoid arthritis, which is another chronic inﬂammatory
disease.32 It has also been shown that MPV is positively associated
with inﬂammatory markers and disease activity in this rheumatic
disease. With regard to psoriasis, a chronic, recurrent inﬂammato-
ry skin disease, Karabudak et al.31 emphasized that the hyperco-
agulable state in psoriasis may be associated with systemic
inﬂammation, and they showed an increased MPV in psoriasis
patients compared to controls.
Tozkoparan et al. showed that active tuberculosis patients had
high MPVs with considerable correlation with the radiological
extent of tuberculosis.33 Van der Lelie et al., in patients with
septicemia, showed that MPVwas high and reached normal values
after one week of treatment in patients who responded favorably
to antibiotic treatment.34 HighMPV has also been demonstrated in
patients with septic shock by Dastugue et al.35 In addition, Becchi
O. Gunebakmaz et al. / International Journal of Infectious Diseases 14 (2010) e982–e985 e985et al. demonstrated that MPV gradually decreased in survivors of
sepsis, as it increased in non-survivors.36
From all this research we came to the conclusion that MPV does
not only represent platelet activation, but also infection and
inﬂammation status. This was another hypothesis that led us to
investigate MPV in IE patients. We wondered if this parameter
could be used in IE as a marker of recovery, in the same way as ESR
and hs-CRP, and we found this to be the case.
AlthoughWallace et al.37 found that high hs-CRP levels and ESRs
did not have any prognostic implication and did not predict in-
hospital mortality or 6-month mortality, in many studies, linear
relationships between these parameters and prognosis have been
demonstrated .38 Similarly, we have shown signiﬁcantly higher hs-
CRP levels andESRs in fatal casesof IE than innon-fatal cases.Wealso
conﬁrm that highMPV levels are associatedwith a poor prognosis in
IE because of the higher levels in fatal and complicated cases.
To our knowledge, this is the ﬁrst research in the literature to
evaluate MPV in IE patients. From this research we are aware that
there is signiﬁcant overlap between the MPV values in patients
with and without emboli. We are also aware that hs-CRP and ESRs
are reliable, well-known disease activity markers. However, the
measurement ofMPV as a routinely studied parameter bymost full
blood count analyzers is very easy and cheap. Consequently, it can
be used as a practical disease activity marker in the follow-up
period, like hs-CRP and ESR. Clinicians should be alert to high MPV
values in IE patients because of the high complications rate.
Conﬁrmation of our results in future studies would be valuable for
the management of IE.
There are two main limitations to our study. Firstly, our results
are retrospective; secondly, the number of patients included in the
study is too few to draw deﬁnite conclusions from the results.
In conclusion, MPV can be used as an activity criterion in IE, like
ESR and hs-CRP. Also, a high MPV is associated with a poor
prognosis and adverse outcomes, and predicts complications
including embolic complications and death. Further studies,
including prospective, randomized studies involving a greater
number of patients are needed to clarify the usefulness of MPV in
the management of IE.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Hoen B, Alla F, Selton-Suty C, Be´guinot I, Bouvet A, Brianc¸on S, et al. Changing
proﬁle of infective endocarditis: results of a 1-year survey in France. JAMA
2002;288:75–81.
2. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;363:139–49.
3. Tleyjeh IM, Steckelberg JM,MuradHS, Anavekar NS, GhomrawiHM,Mirzoyev Z,
et al. Temporal trends in infective endocarditis: a population-based study in
Olmsted County, Minnesota. JAMA 2005;293:3022–8.
4. Nissen H, Nielsen PF, Frederiksen M, Helleberg C, Nielsen JS. Native valve
infective endocarditis in the general population: a 10-year survey of the clinical
picture during the 1980s. Eur Heart J 1992;13:872–7.
5. Hart RG, Foster JW, Luther MF, Kanter MC. Stroke in infective endocarditis.
Stroke 1990;21:695–700.
6. Stewart JA, Silimperi D, Harris P, Wise NK, Fraker Jr TD, Kisslo JA. Echocardio-
graphic documentation of vegetative lesions in infective endocarditis: clinical
implications. Circulation 1980;61:374–80.
7. Ileri M, Alper A, Senen K, Durmaz T, Atak R, Hisar I, et al. Effect of infective
endocarditis on blood coagulation and platelet activation and comparison of
patients with to those without embolic events. Am J Cardiol 2003;91:689–92.
8. Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H. The
presence of infection-related antiphospholipid antibodies in infective endocar-
ditis determines a major risk factor for embolic events. J Am Coll Cardiol
1999;33:1365–71.9. Sandhaus LM, Meyer P. How useful are CBC and reticulocyte reports to clin-
icians? Am J Clin Pathol 2002;118:787–93.
10. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular
disease. Blood Coagul Fibrinolysis 1996;7:157–61.
11. Kapsoritakis AN, Koukourakis MI, Sﬁridaki A, Potamianos SP, Kosmadaki MG,
Koutroubakis IE, et al. Mean platelet volume: a useful marker of inﬂammatory
bowel disease activity. Am J Gastroenterol 2001;96:776–81.
12. Li JS, Sexton DJ, Mick N, Nettles R, Fowler Jr VG, Ryan T, et al. Proposed
modiﬁcations to the Duke criteria for the diagnosis of infective endocarditis.
Clin Infect Dis 2000;30:633–8.
13. Duval X, Leport C. Prophylaxis of infective endocarditis: current tendencies,
continuing controversies. Lancet Infect Dis 2008;8:225–32.
14. Thiene G, Basso C. Pathology and pathogenesis of infective endocarditis in
native heart valves. Cardiovasc Pathol 2006;15:256–63.
15. Bashore TM, Cabell C, Fowler Jr V. Update on infective endocarditis. Curr Probl
Cardiol 2006;31:274–352.
16. Yavuz SS, ErenM, Yavuz A, Bic¸er Y, Koc¸ak F, Bilgen F, et al. Infective endocarditis:
evaluation of 58 cases (in Turkish). Klimik Dergisi 2003;16:55–62.
17. Hoesley CJ, Cobbs CG. Endocarditis at the millennium. J Infect Dis
1999;179(Suppl 2):360–3.
18. Moreillon P. Endocarditis and endarteritis. In: Armstrong D, Cohen J, editors.
Infectious diseases. London: Mosby; 1999. p. 2.50.1–2.50.10.
19. Hogevik H, Olaison L, Andersson R, Lindberg J, Alestig K. Epidemiologic aspects
of infective endocarditis in an urban population. A 5-year prospective study.
Medicine (Baltimore) 1995;74:324–39.
20. Cetinkaya Y, Akova M, Akalin HE, As¸c¸iog˘lu S, Hayran M, Uzuns O, et al. A
retrospective review of 228 episodes of infective endocarditis where rheumatic
valvular disease is still common. Int J Antimicrob Agents 2001;18:1–7.
21. C¸aylan R, Aydın K, Kaygusuz S, Ko¨ksal I, Orem C. Otuziki infektif endokardit
atag˘ının deg˘erlendirilmesi. Flora 2001;6:267–73.
22. Jones Jr HR, Siekert RG. Neurological manifestations of infective endocarditis:
review of clinical and therapeutic challenges. Brain 1989;112:1295–315.
23. Jaffe WM, Morgan DE, Pearlman AS, Otto CM. Infective endocarditis, 1983-
1988: echocardiographic ﬁndings and factors inﬂuencing morbidity and mor-
tality. J Am Coll Cardiol 1990;15:1227–33.
24. Anavekar NS, Tleyjeh IM, Anavekar NS, Mirzoyev Z, Steckelberg JM, Haddad C,
et al. Impact of prior antiplatelet therapy on risk of embolism in infective
endocarditis. Clin Infect Dis 2007;44:1180–6.
25. Chan KL, Dumesnil JG, Cujec B, Sanﬁlippo AJ, Jue J, Turek MA, et al. Investigators
of theMulticenter Aspirin Study in Infective Endocarditis. A randomized trial of
aspirin on the risk of embolic events in patients with infective endocarditis. J
Am Coll Cardiol 2003;42:775–80.
26. Valtonen V, Kuikka A, Syrja¨nen J. Thrombo-embolic complications in bacter-
aemic infections. Eur Heart J 1993;14:20–3.
27. Macko RF, Ameriso SF, Barndt R, CloughW,Weiner JM, Fisher M. Precipitants of
brain infarction: roles of preceding infection/inﬂammation and recent psycho-
logical stress. Stroke 1996;27:1999–2004.
28. Syrja¨nen J, Valtonen VV, Iivanainen M. Preceding infection as an important risk
factor for ischemic brain infarction in young andmiddle aged patients. Br Med J
1988;296:1156–60.
29. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantiﬁcation.
Eur Heart J 2001;22:1561–71.
30. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Bulur S, et al. The platelet functions in
patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the
mean platelet volume and platelet mass. Platelets 2010;21:126–31.
31. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y.
Inﬂammation and hypercoagulable state in adult psoriatic men. Acta Derm
Venereol 2008;88:337–40.
32. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Ozhan H, et al. The platelet indices in
patients with rheumatoid arthritis: mean platelet volume reﬂects disease
activity. Platelets 2010;21:122–5.
33. Tozkoparan E, Deniz O, Ucar E, Bilgic H, Ekiz K. Changes in platelet count and
indices in pulmonary tuberculosis. Clin Chem Lab Med 2007;45:1009–13.
34. Van der Lelie J, Von dem Borne AK. Increased mean platelet volume in
septicaemia. J Clin Pathol 1983;36:693–6.
35. Dastugue N, Picheloup F, Sie P, Genestal M, Cathala B, Boneu B. Increase inmean
platelet volume in shock-related thrombocytopenia. Nouv Presse Med
1982;11:2899–901.
36. Becchi C, Al MalyanM, Fabbri LP, Marsili M, Boddi V, Boncinelli S. Mean platelet
volume trend in sepsis: is it a useful parameter? Minerva Anestesiol
2006;72:749–56.
37. Wallace SM, Walton BI, Kharbanda RK, Hardy R, Wilson AP, Swanton RH.
Mortality from infective endocarditis: clinical predictors of outcome. Heart
2002;88:53–60.
38. Inanc¸ T, Kaya MG, Kaya EG, Dog˘an A, Ardıc¸ I, Dog˘du O, et al. Infective endocar-
ditis: retrospective evaluation of 27 patients (in Turkish). Tıp Aras¸tırmaları
Dergisi 2007;5:91–9.
